You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2018PD59-07 RISK FACTORS OF PHARMACOTHERAPY FOR STORAGE SYMPTOMS AFTER TRANSURETHRAL RESECTION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA Cheng-Han Tsai, Yu-Hua Fan, and Alex T.L. Lin Cheng-Han TsaiCheng-Han Tsai More articles by this author , Yu-Hua FanYu-Hua Fan More articles by this author , and Alex T.L. LinAlex T.L. Lin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2807AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Storage symptoms in older men may occur either secondary to or independent from benign prostatic hyperplasia (BPH). Surgical management with transurethral resection of the prostate (TURP) may be indicated in some BPH patients. Pharmacotherapy for storage symptoms may be warranted for those who have storage symptoms not effectively treated by surgery or develop de novo storage symptoms. This study analyzed the risk factors of the use of antimuscarinics or beta-3 agonist after TURP in BPH patients. METHODS We retrospectively reviewed 391 patients with BPH who underwent TURP between January 2015 and December 2016. All patients received preoperative assessment with International Prostate Symptom Score, uroflowmetry, prostate volume and intravesical prostatic protrusion (IPP). Postoperative pharmacotherapy for storage symptoms was defined as the prescription of antimuscarinics or beta-3 agonist 3 months after TURP for more than 3 months. We evaluated the effects of comorbidities, symptoms severity, results of preoperative evaluation, and TURP-related variables for postoperative prescription of antimuscarinics or beta-3 agonist. RESULTS Of 391 patients included in this study, 46 (11.8 %) received postoperative pharmacotherapy for storage symptoms after TURP. Patients with postoperative pharmacotherapy were significantly older than those without (77.4±7.8 vs 74.4±9.9 years, p = 0.024). Patients underwent bipolar TURP tended to use postoperative pharmacotherapy compared with those underwent unipolar TURP (15.6 % vs 6.6 %, p = 0.007). More patients with preoperative IPP > 1cm used postoperative pharmacotherapy than those with preoperative IPP < 0.5cm (14.2 % vs 5.5 %, p = 0.037). Preoperative acute urinary retention and preoperative medications for storage symptoms did not correlate with postoperative pharmacotherapy. In univariate logistic regression analysis, patients with age older than 75 years (OR, 3.04; 95% CI 1.55-5.98; p=0.001) or underwent bipolar TURP (OR, 2.60; 95% CI 1.28-5.28; p=0.008) had higher risks for postoperative pharmacotherapy. Furthermore, multivariate logistic regression analysis revealed that age > 75 years (OR, 2.84; 95% CI 1.21-6.62; p=0.016), IPP > 1cm (OR, 3.61; 95% CI 1.00-13.07; p=0.050) and bipolar TURP (OR, 4.23; 95% CI 1.53-11.71; p=0.005) were the significant risk factors for postoperative pharmacotherapy. CONCLUSIONS Advanced patient age, IPP and bipolar TURP correlated significantly with the postoperative pharmacotherapy for storage symptoms after TURP © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1142-e1143 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Cheng-Han Tsai More articles by this author Yu-Hua Fan More articles by this author Alex T.L. Lin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...